The study of a novel sorafenib derivative HLC-080 as an antitumor agent.
In this study, our objective is to evaluate the potential of a novel Sorafenib derivative, named HLC-080, as a new anticancer agent for colon cancer. We firstly carried out MTT assay, colony formation assay, flow cytometry analysis and transwell invasion assay to determine effect of our compound HLC...
Main Authors: | Ke Tang, Can Luo, Yan Li, Chenshu Lu, Wanqi Zhou, Haihong Huang, Xiaoguang Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4086976?pdf=render |
Similar Items
-
Antitumor activity of sorafenib on colorectal cancer
by: Turgut Kacan, et al.
Published: (2016-08-01) -
HLC Project 2018: Jagiellonian University excavations in southern Jordan
by: Piotr Kołodziejczyk, et al.
Published: (2019-12-01) -
HLC Project 2017. Jagiellonian University excavations in southern Jordan
by: Piotr Kołodziejczyk, et al.
Published: (2018-12-01) -
Fabricating a novel HLC-hBMP2 fusion protein for the treatment of bone defects
by: Chen, Zhuoyue, et al.
Published: (2020) -
Discovery of Novel Quinazoline Derivatives as Potent Antitumor Agents
by: Zhenxi Niu, et al.
Published: (2022-06-01)